Sujet(s)
Col de l'utérus/anatomopathologie , Conisation/effets indésirables , Composés du fer III/administration et posologie , Hémostase chirurgicale/méthodes , Hémostatiques/administration et posologie , Hémorragie postopératoire/prévention et contrôle , Sulfates/administration et posologie , Administration par voie vaginale , Adulte , Sujet âgé , Femelle , Humains , Adulte d'âge moyen , Hémorragie postopératoire/étiologie , Études rétrospectivesRÉSUMÉ
Heterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy of human papillomavirus (HPV) type 16-associated vulval intraepithelial neoplasia (VIN). In the present study, 10 women with HPV 16-positive high grade VIN, previously primed with TA-HPV, received three booster immunisations with TA-CIN. All but one demonstrated HPV 16-specific proliferative T-cell and/or serological responses following vaccination. Three patients additionally showed lesion shrinkage or symptom relief, but no direct correlation between clinical and immunological responses was seen.
